DDInter1744 DDInter1763
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) binds {v} (Gene) EBP
EBP {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) upregulates {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Febrile neutropenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Tamoxifen {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Tamoxifen (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Temsirolimus (Compound)
Tamoxifen (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Temsirolimus (Compound)
Tamoxifen (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Temsirolimus (Compound)
Tamoxifen (Compound) binds EBP (Gene) and EBP (Gene) is downregulated by Temsirolimus (Compound)
Tamoxifen (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated by Temsirolimus (Compound)
Tamoxifen (Compound) causes Febrile neutropenia (Side Effect) and Febrile neutropenia (Side Effect) is caused by Temsirolimus (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)